Leukemia Gene Fusion Detection with Interpretation

Label Mnemonic:	HEMELEUK
Epic code:	LAB8916
Downtime form:	Doctor/Provider Orders - Pathology Molecular

Molecular Pathology
6240 RCP
384-9568

Specimen(s):

Blood, Bone Marrow Aspirate, Tissue

Specimen Instructions:

Testing requires dedicated collection tube.

Collection Medium:

Pink top tube 6 mL (K2-EDTA)

Minimum:

Whole blood (EDTA anti-coagulated; 6 mL pink top tube) or bone marrow aspirate (EDTA anti-coagulated; pink or lavender top tube) or tissue formalin fixed and paraffin embedded.

Rejection Criteria:

Tumor specimens containing less than 20% tumor cells may be unacceptable.

Delivery Instructions:

Store and send whole blood refrigerated. DO NOT CENTRIFUGE.

Testing Schedule:

Testing is batched.

Turn Around Time:

7-10 days upon receipt in laboratory

Comments:

Testing is used for identification and characterization of lymphoid and myeloid malignancies as defined by the World Health Organization (WHO) 2017 Classification of Tumors of Hematopoietic and Lymphoid Tissues. It involves RNA next generation sequencing (NGS) using Anchored Multiplex Amplification and NGS of 42 target genes.

This assay is used to detect these alternative RNA fusions and variants in the following genes: ABL1, ABL2, BLNK, CBFB, CBL, CCND2, CRLF2, CSF1R, DGKH, DNTT, DUSP22, EPOR, ETV6, FGFR1, FLT3, IKZF1, IL2RB, IRF4, JAK2, JAK3, KMT2A, LYN, MECOM, MKL1, MYH11, NTRK3, NUP214, NUP98, PBX1, PDGFRA, PDGFRB, PML, PTK2B, RARA, RBM15, RUNX1, RUNX1T1, SH2B3, TCF3, TP63, TSLP, and TYK.

Results Reported: Fusion or variants detected.

Methodology:

Reverse transcription, anchored multiplexed PCR for targeted next-generation sequencing is performed on RNA isolated from bone marrow, blood or formalin-fixed paraffin embedded tissue.

CPT Code:

81450